Minute Molecular’s DASH Point-of-Care COVID-19 Rapid PCR Test Gains FDA Emergency Use Authorization
Retrieved on:
Wednesday, March 16, 2022
Minute Molecular Diagnostics today announced that the U.S. Food and Drug Administration (FDA) granted an Emergency Use Authorization (EUA) for its rapid DASH SARS-CoV-2/S Test.
Key Points:
- Minute Molecular Diagnostics today announced that the U.S. Food and Drug Administration (FDA) granted an Emergency Use Authorization (EUA) for its rapid DASH SARS-CoV-2/S Test.
- Minute Moleculars polymerase chain reaction (PCR) test operates on a small instrument called the DASH Analyzer, which consolidates the entire PCR testing process (sample extraction and PCR) providing a result in approximately 15 minutes.
- DASH provides central laboratory quality COVID-19 PCR results at the point of care in approximately the same time as an antigen test.
- The simplicity of the DASH test adds an important, new tool for schools, universities, congregate care settings, and workplaces.